Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)

Episode 221

0:00-34:55

Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure. So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment. In part three of our series and ahead of Diabetes Awareness Month, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes, the realities of making gene therapies at scale, and where a potential one-time treatment could fit alongside GLP-1s. 02:21 Meet Ryan Confer and Genprex 09:49 What gene therapy can offer patients that GLP-1s cannot 12:36 How GPX-002 works and the type 2 diabetes data presented at ASGCT 17:22 Working with a CDMO to manufacture an AAV gene therapy at scale 20:07 Standing out from GLP-1s and stem cell approaches in diabetes 27:59 Diabetes Awareness Month and the prospect of a functional cure Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Publisher

Beyond Biotech - the podcast from Labiotech

Published

October 30, 2026

Duration

35 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Labiotech

BB

Beyond Biotech - the podcast from Labiotech

@beyondbiotechthepodcastfroml

#genprexbets #genetherapy #diabetes

The Nile